News – Page 26 – Alligator Bioscience

2022-09-14

Alligator Bioscience Presents Additional Data from mitazalimab OPTIMIZE-1 Phase 1b/2 Trial at AACR Special Conference on Pancreatic Cancer 2022

Data from Phase 1b dose escalation part of the study shows that mitazalimab combined with mFOLFIRINOX is safe and well tolerated 900 µg/kg d ...

2022-09-06

Lund, Sweden, September 6, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives w ...

2022-07-12

Regulatory

· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data be ...

2022-05-31

ATOR-1017 demonstrates an excellent clinical profile as a potential best-in-class 4-1BB monoclonal antibody ATOR-1017 was safe and well tole ...

2022-05-09

Lund, Sweden, May 9, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Staffan Encrantz and Den ...

2022-05-05

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2022-04-27

Regulatory

A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key ass ...

2022-04-22

LUND (Sweden) – April 22, 2022 – Alligator Bioscience will host a conference call (in English) for investors, analysts and media on Wednesda ...

2022-04-05

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...